1
|
Gondran-Tellier B, Abdallah R, Sichez PC, Akiki A, Toledano H, Gaillet S, Delaporte V, Karsenty G, Bastide C, Daniel L, Garcia S, Rossi D, Lechevallier E, Boissier R, Baboudjian M. Continuous saline bladder irrigation after blue light transurethral resection of bladder tumor increases recurrence-free survival in low- to intermediate-risk non-muscle invasive bladder cancer. Prog Urol 2021; 31:316-323. [PMID: 33663939 DOI: 10.1016/j.purol.2021.01.011] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2020] [Revised: 12/30/2020] [Accepted: 01/29/2021] [Indexed: 11/15/2022]
Abstract
OBJECTIVES To evaluate the efficacy of Continuous Saline Bladder Irrigation (CSBI) after blue light transurethral resection of bladder tumor (TURBT) to prevent recurrence of low- to intermediate-risk Non-Muscle Invasive Bladder Cancer (NMIBC). PATIENTS AND METHODS We conducted a retrospective study including patients with low- to intermediate-risk NMIBC who underwent TURBT in two urological centers between January 2017 and December 2018. Each TURBT was performed using blue light after intravesical instillation of hexaminolaevulinic acid. The experimental group included patients who received CSBI while the control group included patients without CSBI. When practice, CSBI was started immediately after the surgery and was interrupted 24 hours thereafter. Low-risk NMIBC had a surveillance while intermediate NMIBC had 8 adjuvant endovesical instillations of Mitomycin. The primary endpoint was bladder tumor recurrence free-survival which was defined as the time between the initial TURBT and the date of TURBT for bladder recurrence. RESULTS A total of 167 patients (median age: 71 years) were included: 20% female, 15% low-risk, 85% intermediate-risk NMIBC. CSBI was performed in 95 cases (57%). No complication related to irrigation was reported. Bladder recurrence was observed in 55 cases (32.9%): 22 (23.1%) in the CSBI group vs. 33 (45.8%) in the control group (P=0.002). Multivariate stepwise logistic regression analysis with backward selection revealed that CSBI (HR 0.47 [0.27-0.81]; P=0.006) and MMC (HR 0.55 [0.31-0.95]; P=0.034) were significantly associated with reduced risk of bladder recurrence. CONCLUSIONS Continuous saline bladder irrigation reduced the risk of bladder recurrence after blue light TURBT in patients with low- to intermediate-risk NMIBC while being safe. Prospective randomized study is needed to confirm these results. LEVEL OF EVIDENCE 3.
Collapse
Affiliation(s)
- B Gondran-Tellier
- Department of Urology and Kidney Transplantation, APHM, Conception Academic Hospital, Aix-Marseille University, Marseille, France
| | - R Abdallah
- Department of Urology and Kidney Transplantation, APHM, Conception Academic Hospital, Aix-Marseille University, Marseille, France
| | - P C Sichez
- Department of Urology and Kidney Transplantation, APHM, Conception Academic Hospital, Aix-Marseille University, Marseille, France
| | - A Akiki
- Department of Urology and Kidney Transplantation, APHM, Conception Academic Hospital, Aix-Marseille University, Marseille, France
| | - H Toledano
- Department of Urology, APHM, Nord University Hospital, Aix-Marseille University, Marseille, France
| | - S Gaillet
- Department of Urology and Kidney Transplantation, APHM, Conception Academic Hospital, Aix-Marseille University, Marseille, France
| | - V Delaporte
- Department of Urology and Kidney Transplantation, APHM, Conception Academic Hospital, Aix-Marseille University, Marseille, France
| | - G Karsenty
- Department of Urology and Kidney Transplantation, APHM, Conception Academic Hospital, Aix-Marseille University, Marseille, France
| | - C Bastide
- Department of Urology, APHM, Nord University Hospital, Aix-Marseille University, Marseille, France
| | - L Daniel
- Department of Pathological Anatomy and Cytology, APHM, Conception Academic Hospital, Aix-Marseille University, Marseille, France
| | - S Garcia
- Department of Pathological Anatomy and Cytology, APHM, Nord University Hospital, Aix-Marseille University, Marseille, France
| | - D Rossi
- Department of Urology, APHM, Nord University Hospital, Aix-Marseille University, Marseille, France
| | - E Lechevallier
- Department of Urology and Kidney Transplantation, APHM, Conception Academic Hospital, Aix-Marseille University, Marseille, France
| | - R Boissier
- Department of Urology and Kidney Transplantation, APHM, Conception Academic Hospital, Aix-Marseille University, Marseille, France
| | - M Baboudjian
- Department of Urology and Kidney Transplantation, APHM, Conception Academic Hospital, Aix-Marseille University, Marseille, France.
| |
Collapse
|
2
|
Atamian A, Sichez PC, Michel F, Bandelier Q, Fall M, Gaillet S, Azoulay JP, Lechevallier E, Karsenty G. [Intradetrusor injections of botulinum toxin A to treat urinary incontinence due to bladder overactivity during idiopathic Parkinson's disease]. Prog Urol 2021; 31:430-438. [PMID: 33579624 DOI: 10.1016/j.purol.2021.01.004] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2019] [Revised: 01/16/2021] [Accepted: 01/18/2021] [Indexed: 11/17/2022]
Abstract
INTRODUCTION During idiopathic Parkinson's disease (IPD), lower urinary tract symptoms and dysfunctions are frequent, dominated by overactive bladder and detrusor overactivity (OAB, DO). Intradetrusor Injection (IDI) of Botulinum Toxin A (BTA) is recommended as second-line treatment for neurogenic urinary incontinence related to DO in multiple sclerosis or spinal cord injury patients. However, there is little data on BTA IDI to treat incontinence owing to OAB and DO during idiopathic Parkinson's disease. The objective of this study is to evaluate efficacy and tolerance of BTA IDI in patients suffering IPD. PATIENTS AND METHODS We conducted a retrospective study in IPD patients treated with BTA IDI from 2012 to 2018. For each patient we compared patient clinical and urodynamic data at baseline before the first injection and 8 weeks following the injection. We defined 3 levels of effects (perfect, improved, failure), corresponding to 3-dimension composite criteria: clinical, quality of life (Likert scale), urodynamics. RESULTS Sixteen patients were included from 2012 to 2018. The median age was 73 (70-78.25). The median number of micturition/day before and after TBA was 13 (10-16) and 9 (6.75-13.25) (p=0.022). The median number of pad used/day before and after BTA was 5.4 (2-5) and 1 (0-5) (p=0.035). Median USP scores for OAB was 15.5 (11.75-20) and 14 (6.75-15.25). Median score on the Likert scale was 1 (0-1.5) meaning "slight improvement" felt by the patient. The median maximum cystometric capacity raised from 130cm3 (41.25-187.75) to 217cm3 (165-376.75) (p=0,013). Among the patients, 20% had a perfect result, 40% were significantly improved and in 40% TBA injections failed. After TBA 4/14 patients (28%) needed intermittent self-catheterization. No severe side effect was observed. CONCLUSION In this retrospective study we observe some short-term efficacy of TBA IDI to treat urinary incontinence owing to OAB/DO in patients with IPD in 60% of patients. These results are consistent with findings from previous retrospective studies. Prospective data coming from larger cohorts are now tremendously needed to clarify the best patient responders profiles, the actual TBA dose, and eventually to define TBA IDI place in the therapeutic algorithm of IPD patients' incontinence. LEVEL OF EVIDENCE 4.
Collapse
Affiliation(s)
- A Atamian
- Hôpital Conception, 147, boulevard Baille, 13005 Marseille, France.
| | - P C Sichez
- Hôpital Conception, 147, boulevard Baille, 13005 Marseille, France.
| | - F Michel
- Hôpital Conception, 147, boulevard Baille, 13005 Marseille, France.
| | - Q Bandelier
- Hôpital Conception, 147, boulevard Baille, 13005 Marseille, France.
| | - M Fall
- Hôpital Timone, 264, rue Saint-Pierre, 13005 Marseille, France.
| | - S Gaillet
- Hôpital Conception, 147, boulevard Baille, 13005 Marseille, France.
| | - J P Azoulay
- Hôpital Timone, 264, rue Saint-Pierre, 13005 Marseille, France.
| | - E Lechevallier
- Hôpital Conception, 147, boulevard Baille, 13005 Marseille, France.
| | - G Karsenty
- Hôpital Conception, 147, boulevard Baille, 13005 Marseille, France.
| |
Collapse
|
3
|
Michel F, Negre T, Baboudjian M, Al-Balushi K, Oliva J, Gondran-Tellier B, Sichez PC, Delaporte V, Gaillet S, Aikiki A, Faure A, Karsenty G, Lechevallier E, Boissier R. Micro-percutaneous nephrolithotomy (Microperc) for renal stones, outcomes and learning curve. Prog Urol 2021; 31:91-98. [DOI: 10.1016/j.purol.2020.03.006] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2019] [Revised: 12/27/2019] [Accepted: 03/12/2020] [Indexed: 10/24/2022]
|
4
|
Sichez PC, Baboudjian M, Depalorte V, Karsenty G, Lechevallier É, Boissier R. [Long term renal function outcomes and predictive factors of chronic renal failure after living kidney donation]. Prog Urol 2019; 29:496-503. [PMID: 31383507 DOI: 10.1016/j.purol.2019.07.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2019] [Revised: 06/23/2019] [Accepted: 07/02/2019] [Indexed: 11/15/2022]
Abstract
INTRODUCTION Living donor kidney transplants give the best results in term of renal function and are the principal solutions for the transplant shortage. However, donors selection and kidney function evaluation after surgery are essential. The objective of this study was to evaluate the prevalence and to identify the predictive factors of chronic renal failure for the donor, after living donor nephrectomy. MATERIALS AND METHODS It was a retrospective and monocentric study, including all the patients who underwent a living donor nephrectomy from 2007 to 2015 at the hospital of the Conception in Marseille. The primary study endpoint was renal function mesured by the glomerular filtration rate (GFR in mL/min) at 1 year and 5 years after surgery. The identification of moderate kidney failure predictive factors was achieved by an univariate and a multivariate analysis under Cox model. RESULTS Ninety-one patients were included. There was 40,7 % of men and media nage was 49 years (21; 70). Median pre-operative GFR was 94mL/min (67; 160). Median follow-up was 24 months (1; 120). Post operative GFR at 1 month, 1 year and 5 years was respectively 63mL/min (33; 90), 65mL/min (38; 107) and 67mL/min (56; 126) ans significantly lower than pre operative GFR (respectively P<0,001, P<0,001 et P=0,005). The prevalence of moderate kidney failure at 1 month, 1 year and 5 years was respectively 43,1 %, 33,3 % ans 25 %. In univariate and multivariate analysis, the only parametre significantly associated with a 1 year GFR>60mL/min wasp re operative GFR>90mL/min OR 3,61 IC95 % (1,27; 10,28) P=0,02. CONCLUSION Living donor nephrectomy leads to an important medium to long term loss of renal function. Donors with pre operative GFR<90mL/min should benefit from a rigorous supervision and nephrological care. LEVEL OF EVIDENCE 3.
Collapse
Affiliation(s)
- P C Sichez
- Service du Pr Lechevallier, Hôpital de la Conception, 147, Bd Baille 13005 Marseille, France.
| | - M Baboudjian
- Service du Pr Lechevallier, Hôpital de la Conception, 147, Bd Baille 13005 Marseille, France.
| | - V Depalorte
- Service du Pr Lechevallier, Hôpital de la Conception, 147, Bd Baille 13005 Marseille, France.
| | - G Karsenty
- Service du Pr Lechevallier, Hôpital de la Conception, 147, Bd Baille 13005 Marseille, France.
| | - É Lechevallier
- Service du Pr Lechevallier, Hôpital de la Conception, 147, Bd Baille 13005 Marseille, France.
| | - R Boissier
- Service du Pr Lechevallier, Hôpital de la Conception, 147, Bd Baille 13005 Marseille, France.
| |
Collapse
|
5
|
Al-Balushi K, Martin N, Loubon H, Baboudjian M, Michel F, Sichez PC, Martin T, Di-Crocco E, Gaillet S, Delaporte V, Akiki A, Faure A, Karsenty G, Lechevallier E, Boissier R. Comparative medico-economic study of reusable vs. single-use flexible ureteroscopes. Int Urol Nephrol 2019; 51:1735-1741. [PMID: 31317310 DOI: 10.1007/s11255-019-02230-1] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2019] [Accepted: 07/08/2019] [Indexed: 11/30/2022]
Abstract
PURPOSE Reusable flexible-ureteroscopes (fURS) require personnel and budget for processing and repairing, whereas single-use fURS were recently developed. After exclusive reusable fURS since 2011, we experienced high repair costs and single-use fURS were therefore introduced in mid-2017. We aimed to evaluate economic and practical advantages and disadvantages of reusable versus single-use fURS. MATERIALS AND METHODS First, we evaluated the incidence of breakage and repairs of reusable fURS in 2017. We assessed the overall operational costs of reusable fURS including purchase, processing, and repairing in our institution from 2011 to 2017. Following our experience, we created a model to compare operation costs/procedure of single-use fURS with reusable fURS depending on repair costs. RESULTS In 2017, repair costs of reusable fURS increased by 345% compared with the period 2011-2016, causing: a median unavailability per reusable fURS of 200 days/year (100-249), median number of functioning fURS 0/5-3/5 per operating day, while unavailability of reusable fURS had become the first reason for cancellation of procedure. Since it was introduced, single-use fURS accounted for 59% of the flexible ureteroscopy activity. Taking into account the costs of processing, maintenance and repair, in 2011-2016 versus 2017, the single-use fURS was cost-effective compared with the reusable fURS until the 22nd procedure versus the 73rd procedure, respectively. CONCLUSIONS After years of exclusive reusable fURS, the rising incidence of breakage not only increased maintenance costs but also hampered daily activity owing to unavailability of the devices. The introduction of single-use with reusable fURS provided substantial help to maintain our activity.
Collapse
Affiliation(s)
- Khalid Al-Balushi
- Department of Urology and Kidney Transplantation, APHM, Conception University Hospital, Aix-Marseille University, 13005, Marseille, France
| | - Nathalie Martin
- APHM, Conception University Hospital, Central Pharmacy, Marseille, France
| | - Hélène Loubon
- Department of Urology and Kidney Transplantation, APHM, Conception University Hospital, Aix-Marseille University, 13005, Marseille, France
| | - Michael Baboudjian
- Department of Urology and Kidney Transplantation, APHM, Conception University Hospital, Aix-Marseille University, 13005, Marseille, France
| | - Floriane Michel
- Department of Urology and Kidney Transplantation, APHM, Conception University Hospital, Aix-Marseille University, 13005, Marseille, France
| | - Pierre-Clément Sichez
- Department of Urology and Kidney Transplantation, APHM, Conception University Hospital, Aix-Marseille University, 13005, Marseille, France
| | - Thomas Martin
- Department of Urology and Kidney Transplantation, APHM, Conception University Hospital, Aix-Marseille University, 13005, Marseille, France
| | - Eugénie Di-Crocco
- Department of Urology and Kidney Transplantation, APHM, Conception University Hospital, Aix-Marseille University, 13005, Marseille, France
| | - Sarah Gaillet
- Department of Urology and Kidney Transplantation, APHM, Conception University Hospital, Aix-Marseille University, 13005, Marseille, France
| | - Veronique Delaporte
- Department of Urology and Kidney Transplantation, APHM, Conception University Hospital, Aix-Marseille University, 13005, Marseille, France
| | - Akram Akiki
- Department of Urology and Kidney Transplantation, APHM, Conception University Hospital, Aix-Marseille University, 13005, Marseille, France
| | - Alice Faure
- Department of Pediatric Surgery, APHM, Timone University Hospital, Aix-Marseille University, Marseille, France
| | - Gilles Karsenty
- Department of Urology and Kidney Transplantation, APHM, Conception University Hospital, Aix-Marseille University, 13005, Marseille, France
| | - Eric Lechevallier
- Department of Urology and Kidney Transplantation, APHM, Conception University Hospital, Aix-Marseille University, 13005, Marseille, France
| | - Romain Boissier
- Department of Urology and Kidney Transplantation, APHM, Conception University Hospital, Aix-Marseille University, 13005, Marseille, France.
| |
Collapse
|